How to discontinue omalizumab in chronic spontaneous urticaria?
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidenceExpert Opinion on Biological Therapy, 2018
- Executive summary of the methods report for ‘The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update’Allergy, 2018
- Role of Biologics and Future Perspectives in the Treatment of UrticariaCurrent Treatment Options in Allergy, 2017
- Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticariaEuropean Journal Of Dermatology, 2017
- Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safetyExpert Opinion on Biological Therapy, 2017
- Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinionEuropean Journal Of Dermatology, 2017
- Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticariaJournal of the European Academy of Dermatology and Venereology, 2016
- Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trialsJournal of Allergy and Clinical Immunology, 2016
- Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1Allergy, 2010